CSL Behring said on August 8 that it has launched a prefilled syringe version of its immunoglobulin agent Hizentra, Hizentra 20% SC Injection 4 g/20 mL, in Japan. The product is the country’s first subcutaneous immunoglobulin now available in a…
To read the full story
Related Article
- CSL Debuts Higher-Dose Hizentra Prefilled Syringe in Japan
August 3, 2026
- Prefilled Syringe Versions of Hizentra Approved in Japan: CSL
January 23, 2024
BUSINESS
- Former Takeda CEO Yasuchika Hasegawa Dies at 80
September 11, 2026
- Takeda R&D Chief Plump to Retire in June 2027
September 11, 2026
- Lasker Win “Not the Finish Line” for Chugai Researchers; Next-Gen Drug Advances
September 11, 2026
- Daiichi Sankyo Wins 203 Billion Yen Lawsuit over Fortis Bid
September 11, 2026
- Silchester Emerges as Suzuken’s Top Shareholder with 10.03% Voting Stake
September 11, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





